GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report.

BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...

If you or someone you love depends on prescription medications, you’ve probably noticed how expensive they’ve become. A new ...

Pet owners now have a new online resource that can help them save money. GoodRx, a company known for offering consumers ...

GoodRx (NASDAQ:GDRX – Free Report) had its price objective reduced by Citigroup from $7.00 to $6.25 in a research note issued ...

Analysts have set 12-month price targets for GoodRx Holdings ... revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including ...

Leerink Partners analyst Michael Cherny has maintained their bullish stance on GDRX stock, giving a Buy rating on January 10.Stay Ahead of the ...

At the 2025 JP Morgan Healthcare Conference, GoodRx’s recently appointed CEO Wendy Barnes highlighted the company’s strategic position to address the gaps in the US healthcare landscape.